Paul Barragan

Summary

Country: France

Publications

  1. ncbi Elastic recoil of coronary stents: a comparative analysis
    P Barragan
    centre hospitalier privé Beauregard, Marseille, France
    Catheter Cardiovasc Interv 50:112-9. 2000
  2. ncbi Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation
    Paul Barragan
    Department of Cardiology, Beauregard Private Hospital Center, Marseille, France
    Catheter Cardiovasc Interv 59:295-302. 2003
  3. ncbi [The Siro-ISR registry: treatment of intra-stent restenosis with the sirolimus stent in the real world]
    P Barragan
    CHP Beauregard, Marseille, France
    Ann Cardiol Angeiol (Paris) 53:45s-46s. 2004
  4. ncbi Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism
    Laurent Bonello
    Departement de Cardiologie, Hopital Universitaire Nord, Faculte de Medecine, Universite de la Mediterranee, Marseille, France
    J Am Coll Cardiol 56:1630-6. 2010
  5. ncbi Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction
    Laurent Bonello
    Departement de Cardiologie, Hopital Universitaire Nord, Aix Marseille University, Marseille, France
    Thromb Haemost 108:101-6. 2012
  6. ncbi Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study
    Laurent Bonello
    Service de cardiologie, Hopital Universitaire Nord, Marseille, France
    J Am Coll Cardiol 51:1404-11. 2008
  7. ncbi Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention
    Nathalie Bonello-Palot
    Departement de Genetique Medicale, Hôpital de la Timone enfant, Marseille, France
    Am J Cardiol 104:1511-5. 2009
  8. ncbi Assessment of the trackability, flexibility, and conformability of coronary stents: a comparative analysis
    Regis Rieu
    Ecole Superieure de Mecanique de Marseille, IRPHE CNRS UMR 6594, IMT, Technopole de Chateau Gombert, Marseille, France
    Catheter Cardiovasc Interv 59:496-503. 2003
  9. ncbi Three-dimensional numerical simulations of physiological flows in a stented coronary bifurcation
    V Deplano
    Equipe de Biomécanique Cardiovasculaire, IRPHE UMR no 6594, Technopole de Chateau Gombert, Marseille, France 2CHP Beauregard, Marseille, France
    Med Biol Eng Comput 42:650-9. 2004
  10. ncbi [Acute myocardial infarction in myocardial bridge treated by coronary stent]
    G Macaluso
    Service de cardiologie, centre hospitalier privé Beauregard, Marseille
    Arch Mal Coeur Vaiss 97:168-71. 2004

Collaborators

Detail Information

Publications15

  1. ncbi Elastic recoil of coronary stents: a comparative analysis
    P Barragan
    centre hospitalier privé Beauregard, Marseille, France
    Catheter Cardiovasc Interv 50:112-9. 2000
    ..The results of in vitro mechanical tests may confirm strongly the interest of a minimum ER in the prevention of the 6-month restenosis...
  2. ncbi Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation
    Paul Barragan
    Department of Cardiology, Beauregard Private Hospital Center, Marseille, France
    Catheter Cardiovasc Interv 59:295-302. 2003
    ..We found a significant difference between group 3 (63.28% +/- 9.56%) and group 4 (39.80% +/- 10.9%; P < 0.0001). VASP phosphorylation analysis may be useful for the detection of coronary SAT...
  3. ncbi [The Siro-ISR registry: treatment of intra-stent restenosis with the sirolimus stent in the real world]
    P Barragan
    CHP Beauregard, Marseille, France
    Ann Cardiol Angeiol (Paris) 53:45s-46s. 2004
  4. ncbi Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism
    Laurent Bonello
    Departement de Cardiologie, Hopital Universitaire Nord, Faculte de Medecine, Universite de la Mediterranee, Marseille, France
    J Am Coll Cardiol 56:1630-6. 2010
    ....
  5. ncbi Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction
    Laurent Bonello
    Departement de Cardiologie, Hopital Universitaire Nord, Aix Marseille University, Marseille, France
    Thromb Haemost 108:101-6. 2012
    ..The present results suggest that 600 mg of clopidogrel may not be able to achieve an optimal PR inhibition in STEMI patients undergoing PCI and more potent drugs may be preferred...
  6. ncbi Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study
    Laurent Bonello
    Service de cardiologie, Hopital Universitaire Nord, Marseille, France
    J Am Coll Cardiol 51:1404-11. 2008
    ....
  7. ncbi Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention
    Nathalie Bonello-Palot
    Departement de Genetique Medicale, Hôpital de la Timone enfant, Marseille, France
    Am J Cardiol 104:1511-5. 2009
    ..Dose adjustment overcomes HTPR in carriers of the CYP2C19 2 allele. BMI is the only independent predictor of failed dose adjustment. Thus, drug underdosage seems to be the main determinant of HTPR...
  8. ncbi Assessment of the trackability, flexibility, and conformability of coronary stents: a comparative analysis
    Regis Rieu
    Ecole Superieure de Mecanique de Marseille, IRPHE CNRS UMR 6594, IMT, Technopole de Chateau Gombert, Marseille, France
    Catheter Cardiovasc Interv 59:496-503. 2003
    ..26 +/- 0.13 (S7) to 0.44 +/- 0.12 mm (S670; P < 0.0001). These results may influence the choice of a particular stent adapted to a specific coronary anatomy...
  9. ncbi Three-dimensional numerical simulations of physiological flows in a stented coronary bifurcation
    V Deplano
    Equipe de Biomécanique Cardiovasculaire, IRPHE UMR no 6594, Technopole de Chateau Gombert, Marseille, France 2CHP Beauregard, Marseille, France
    Med Biol Eng Comput 42:650-9. 2004
    ..5 Nm(-2). These regions could be prone to platelet adhesion and so to thrombo-embolic complications. The analysis of the flow field indicated that it would be judicious to use dedicated bifurcated stents to treat bifurcation lesions...
  10. ncbi [Acute myocardial infarction in myocardial bridge treated by coronary stent]
    G Macaluso
    Service de cardiologie, centre hospitalier privé Beauregard, Marseille
    Arch Mal Coeur Vaiss 97:168-71. 2004
    ..The outcome was good with no recurrence of angina at 16 months and control coronary angiography was totally normal at the 8th month...
  11. ncbi Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures
    M Silvestri
    Cardiology Department, Beauregard Private Hospital Center, Marseille, France
    J Am Coll Cardiol 35:1543-50. 2000
    ..We sought to evaluate immediate and late outcomes after stenting for left main coronary artery (LMCA) stenosis...
  12. ncbi Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial
    Jean Fajadet
    Clinique Pasteur, 45, Avenue du Lombez, 31300 Toulouse, France
    Circulation 111:1040-4. 2005
    ..This analysis examined whether these beneficial effects persist over the longer term...
  13. ncbi Sirolimus for below the knee lesions: mid-term results of SiroBTK study
    Philippe Commeau
    Département de Cardiologie et Radiologie Vasculaire Interventionelles, Polyclinique Les Fleurs, 83190 Ollioules, France
    Catheter Cardiovasc Interv 68:793-8. 2006
    ..To assess the safety and efficacy of sirolimus-eluting stents (SESs) in the treatment of severe intermittent claudication and critical limb ischaemia with "below-the-knee" lesions, unsuitable for surgery...
  14. ncbi Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial
    Marie Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    J Am Coll Cardiol 50:1299-304. 2007
    ..This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents...
  15. ncbi A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
    Marie-Claude Morice
    Institut Cardiovasculaire Paris Sud, Massy, France
    N Engl J Med 346:1773-80. 2002
    ..CONCLUSIONS: As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events...